Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Ceralasertib, Oleclumab, and Monalizumab for Advanced Non-Small Cell Lung Cancer Patients Resistant to PD-1 Inhibitors

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying treatments for advanced non-small cell lung cancer, a type of lung cancer that is common and can be challenging to treat, especially when it becomes resistant to certain therapies. The study is exploring the effectiveness of different treatment strategies, including combinations of medications. One of the main treatments being tested is a combination with a PD-L1 inhibitor called Durvalumab, which is a type of medication that helps the immune system fight cancer. This is compared to Docetaxel, a standard chemotherapy drug used for treating this type of cancer.

The trial involves several experimental medications, including Ceralasertib (also known as AZD6738), which is taken as a tablet and works by inhibiting a protein involved in cancer cell repair. Another medication being tested is Oleclumab (also known as MEDI9447), which is given through an infusion and is designed to target specific proteins on cancer cells. Additionally, Monalizumab (also known as IPH2201) is being studied, which is another infusion-based treatment that helps the immune system recognize and attack cancer cells. The purpose of the study is to assess the anti-tumor activity of these experimental strategies in patients who have not responded to previous treatments.

Participants in the study will receive one of these treatments or a placebo, and their progress will be monitored over a period of time to see how well the cancer is controlled. The study aims to determine the effectiveness of these treatments in controlling the disease and improving patient outcomes. The trial is designed to provide valuable information on new potential treatment options for patients with advanced non-small cell lung cancer who have developed resistance to existing therapies.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes a review of medical history and current health status.

    Eligibility criteria include a confirmed diagnosis of advanced non-small cell lung cancer, age over 18, and specific health conditions such as adequate organ function.

  2. Step 2

    Treatment assignment

    Participants are assigned to one of the treatment groups. The study aims to compare the effectiveness of different treatment strategies involving a combination of medications.

  3. Step 3

    Medication administration

    Participants receive medications according to their assigned group. The medications include ceralasertib, oleclumab, monalizumab, durvalumab, docetaxel, and savolitinib.

    Ceralasertib and savolitinib are administered orally as film-coated tablets.

    Oleclumab, monalizumab, and durvalumab are given through intravenous infusion.

    Docetaxel is administered intravenously.

  4. Step 4

    Monitoring and follow-up

    Regular monitoring is conducted to assess the response to treatment and manage any side effects. This includes physical examinations, imaging tests, and laboratory tests.

    The primary goal is to determine the 12-week disease control rate, while secondary goals include measuring the proportion of patients with complete or partial response and progression-free survival.

  5. Step 5

    Completion of study

    The study is expected to conclude by October 2025. Participants will have a final assessment to evaluate the overall outcomes of the treatment.

Who can join the trial?

12 criteria

  • Must be able and willing to sign a document called an informed consent form, which means you agree to follow the study's rules and procedures.
  • For women, must either be post-menopausal or have a negative pregnancy test if pre-menopausal. Post-menopausal means not having a period for 12 months without another medical reason.
  • Women must not be breastfeeding.
  • Women and men who can have children must agree to use very effective birth control methods during the study and for 6 months after the last study drug. This includes methods like hormonal injections, certain devices placed in the uterus, or surgical procedures like vasectomy or hysterectomy. Using condoms or not having sex at all are also options.
  • Must be over 18 years old.
  • Must have a confirmed diagnosis of advanced or returning **non-small cell lung cancer** (NSCLC). This includes both squamous and non-squamous types, but not a mix with small cell lung cancer.
  • Must have a performance status of 0 or 1 on the **Eastern Cooperative Oncology Group (ECOG)** scale, which measures how well you can carry out daily activities.
  • Must weigh more than 35 kg (about 77 pounds).
  • Must show signs of cancer progression after using certain cancer drugs (PD-1 or PD-L1 inhibitors) for more than 6 weeks but less than 18 weeks. No other treatments should have been given between the last immunotherapy and joining this study.
  • If you have certain genetic changes in your cancer (like **EGFR**, **ALK**, or **ROS1**), you should have already tried specific treatments for those changes.
  • If you have cancer that has spread to the brain (**central nervous system metastases**), it must have been treated, and you should not have any symptoms. You should not be receiving treatment like surgery, radiation, or steroids for it, and it should be at least 14 days since the last treatment.
  • Must have proper functioning of organs and bone marrow, which includes having enough red blood cells, white blood cells, and platelets, as well as normal liver and thyroid function.

Who cannot join the trial?

5 criteria

  • Patients who have a different type of cancer than non-small cell lung cancer cannot participate. This type of cancer affects the lungs and is not the same as other lung cancers.
  • Patients who have not previously been treated with PD-1/PD-L1 monotherapy are excluded. This is a type of treatment that helps the immune system fight cancer.
  • Patients who are not in the age range specified for the study cannot join. The study is open to certain age groups only.
  • Patients who are part of a vulnerable population, such as those who cannot give consent or have certain health conditions, are not eligible.
  • Both male and female patients are eligible, but those who do not meet other criteria will be excluded.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Durvalumab

    is an immune therapy used in this trial. It works by blocking a protein called PD-L1, which can help the immune system recognize and attack cancer cells more effectively. This medication is being tested in combination with other treatments to see if it can improve outcomes for patients with advanced non-small cell lung cancer who have not responded to previous treatments.

  • Docetaxel

    is a type of chemotherapy used in this trial. It works by interfering with the growth and division of cancer cells, which can help slow down or stop the progression of the disease. This medication is being used as a standard treatment to compare the effectiveness of the new immune therapy strategies being tested in the study.

What is already known about the treatment

  • Durvalumab

    Durvalumab is administered as an intravenous infusion, typically given in a clinical setting under the supervision of healthcare professionals. It is currently being studied in clinical trials for its effectiveness in treating advanced non-small cell lung cancer, particularly in patients who have developed resistance to PD-1 inhibitors. The main therapeutic indication for Durvalumab is as an immune checkpoint inhibitor, which works by blocking the PD-L1 protein on cancer cells, thereby enhancing the immune system's ability to attack and destroy these cells. It is classified pharmacologically as a monoclonal antibody used in cancer immunotherapy.

  • Docetaxel

    Docetaxel is administered through an intravenous infusion, usually in a hospital or clinic. It is a well-established chemotherapy drug used in the treatment of various cancers, including non-small cell lung cancer. The primary therapeutic indication for Docetaxel is to inhibit cancer cell growth by disrupting the microtubule network essential for cell division. It belongs to the pharmacological class of taxanes, which are known for their role in cancer chemotherapy.

Investigated diseases

Non-Small Cell Lung Cancer – This is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. It typically starts in the epithelial cells lining the lungs and can grow and spread to other parts of the body if not managed. The disease progresses through stages, beginning with localized tumors and potentially advancing to more widespread involvement of the lungs and other organs. Symptoms may include a persistent cough, chest pain, and difficulty breathing. As the cancer advances, it may lead to more severe respiratory issues and general health decline. Early detection and monitoring are crucial for managing its progression.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-515532-72-00Protocol codePIONeeR TRIALEstimated enrolment130 patientsSponsorAssistance Publique Hopitaux De Marseille

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).